Quick Answer
NewAmsterdam Pharma Co N.V. reported Total Assets of $769.28 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $769.28M | -11.0% |
| 2024 | $864.62M | +149.1% |
| 2023 | $347.10M | -27.5% |
| 2022 | $478.50M | +700.4% |
| 2021 | $59.78M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $786.43M | +79.1% | -3.5% |
| June 30, 2025 | $815.11M | +82.5% | -0.4% |
| March 31, 2025 | $818.41M | +67.5% | -5.3% |
| December 31, 2024 | $864.62M | +149.1% | +96.9% |
| September 30, 2024 | $439.19M | — | -1.7% |
| June 30, 2024 | $446.69M | — | -8.6% |
| March 31, 2024 | $488.46M | — | +40.7% |
| December 31, 2023 | $347.10M | — | — |
- NewAmsterdam Pharma Co N.V. showed a decrease of -11.0% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, NewAmsterdam Pharma Co N.V.’s total assets has grown by 1186.8% (from $59.78 million to $769.28 million).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: